FLASH Proton Radiation Therapy Preserves Ocular Structure and Function Without Compromising Antitumor Efficacy
International Journal of Radiation Oncology*Biology*Physics · 2026
DOI: 10.1016/j.ijrobp.2026.08.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Uri Amit und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Oncology, Univer…. Hauptthemen laut MEDLINE: Proton Therapy, Melanoma, Experimental, Radiation Injuries, Experimental. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. M. Kirby Foundation, National Institutes of Health.
Abstract (Originalsprache)
PURPOSE: To evaluate the protective effects and therapeutic efficacy of FLASH proton radiation therapy (FR) compared with standard proton radiation therapy (SR) in a preclinical model of ocular irradiation. METHODS AND MATERIALS: Mice received bilateral ocular irradiation with SR (≤1 Gy/s) or FR (>40 Gy/s) at identical doses. Longitudinal ocular structure and function were assessed over 5 months using spectral-domain optical coherence tomography, confocal scanning laser ophthalmoscopy, electroretinography, and histopathologic analysis. Tumor control was evaluated in an intraocular B16F10 melanoma model using bioluminescence imaging and histopathology. RESULTS: Dose-response studies identified 24 Gy as the optimal dose, producing substantial visual impairment with SR (39.5% reduction in rod a-wave amplitude, P .05 SR vs FR). CONCLUSIONS: FR provides substantial normal-tissue protection across multiple ocular compartments while preserving therapeutic efficacy, effectively expanding the therapeutic window for ocular radiation therapy. These findings establish proof-of-principle for clinical translation of FR to improve visual outcomes in patients with ocular and orbital malignancies without compromising tumor control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
- FM Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Costas.koumenis@pennmedicine.upenn.edu.
Förderung
- F. M. Kirby Foundation
- National Institutes of Health
Zitieren
APA
Amit, U., Bell, B. A., Hoyek, E. E., Velalopoulou, A., Assenmacher, C. A., Kim, M. M., Verginadis, I. I., Radaelli, E., Ben-Josef, E., Lee, V., Dunaief, J. L., & Koumenis, C. (2026). FLASH Proton Radiation Therapy Preserves Ocular Structure and Function Without Compromising Antitumor Efficacy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.08.045
Vancouver
Amit U, Bell BA, Hoyek EE, Velalopoulou A, Assenmacher CA, Kim MM, et al. FLASH Proton Radiation Therapy Preserves Ocular Structure and Function Without Compromising Antitumor Efficacy. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.08.045
BibTeX
@article{Amit2026,
author = {Amit, Uri and Bell, Brent A and Hoyek, Elias El and Velalopoulou, Anastasia and Assenmacher, Charles-Antoine and Kim, Michele M and Verginadis, Ioannis I and Radaelli, Enrico and Ben-Josef, Edgar and Lee, Vivian and Dunaief, Joshua L and Koumenis, Constantinos},
title = {FLASH Proton Radiation Therapy Preserves Ocular Structure and Function Without Compromising Antitumor Efficacy},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.08.045}
}
EUVIMED